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EFFECT OF INITIAL ANTIRETROVIRAL REGIME ON VIROLOGICAL SUPPRESSION IN CHILDREN IN A 
SOUTHERN AFRICAN URBAN POPULATION: A RETROSPECTIVE RECORD REVIEW  
 
Background  
Since 2010, adult studies and clinical concerns about stavudine (d4T) toxicity had led to the phasing 
out of d4T from many antiretroviral treatment (ART) guidelines globally with substitution by 
abacavir. Recent studies, within Southern Africa, however have shown poorer virological 
suppression with abacavir (ABC) compared to d4T at their respective centres.  
 
Methods  
A retrospective study of HIV-positive children, who had been initiated on ART from 2005 to 2017, 
was conducted at an ART unit at New Somerset hospital, Western Cape, South Africa. Data was 
extracted from clinical notes and electronic medical records and virological suppression reviewed in 
those started on ABC and d4T based regimes.  
 
Results  
A total of 672 children were included in the study with a median age of 8.9 months (interquartile 
range (IQR) 4.1- 24.1 months) in the d4T based group and 11 months (IQR 3.5 - 29.9 months) in the 
ABC group. 64 of the 437 patients in the d4T containing group were transferred out, 15 reported to 
have died, and 49 were lost to follow up within the first 6months on treatment. Of the 181 ABC 
containing regimen group, 1 was transferred out to another care facility, 1 reported death within 
6months of treatment and 2 children were lost to follow up. There was a noted increased risk of 
being virologically unsuppressed at 6months while taking ABC containing regimen compared to a 
d4T containing regimen. . The relative risk of being virologically unsuppressed at 6 months while 
taking abacavir/lopinavir (LPV/r) was 1.39 (95% confidence interval 1.03 to 1.88, p=0.04) compared 
to stavudine/LPV/r. The relative risk of being virologically unsuppressed at 6 months while taking 




Our analysis again raises concerns about virological suppression in the abacavir era of paediatric 
ART, compared to the previous stavudine era, particularly in combination with LPV/r in the younger, 
more vulnerable children. Whether this is because of intrinsic properties of the different 
medications or is a marker of the evolving complexity of the South African ART rollout, may never be 
resolved. However, this is of concern as abacavir and LPV/r appear to be entrenched as first-line 
paediatric ART in a setting where attrition is high, many children are lost to follow up and virologic 
surveillance is not always optimal. Clinicians need to optimize retention strategies, especially of 
young infants, to ensure that children are retained in care, have viral load testing timeously, so that 











Study Protocol  
 
Effect of initial antiretroviral regime on virological suppression in children in a Southern African 
urban population: A retrospective record review  
Study Investigators  
 
Principal Investigator: Dr Dave le Roux  
Co-Investigator: Dr Zeenat Gaibee  
New Somerset Hospital ARV Clinic, Cape Town, South Africa  
 
Introduction  
Paediatric access to antiretroviral treatment (ART) in Sub-Saharan Africa and other low-resource 
settings have demonstrated good early outcomes and studies in high-income countries have 
demonstrated that ART use among children effectively reduces morbidity, hospital admissions and 
increases long-term survival.(1) Lack of affordable and appropriate paediatric formulations have 
limited ART options in South Africa.(2) This study aims to compare virological suppression with 
abacavir to stavudine as well as the effect of concurrent diagnosis with tuberculosis (TB) virological 
suppression, and the medium-term effect on malnutrition.  
 
Background  
Initially the South African ART programme used stavudine (d4T) as a first-line nucleoside reverse 
transcriptase inhibitor (NRTI). Stavudine was palatable and stable at room temperature, had few 
initial complications, and was relatively inexpensive. However late complications like lipodystrophy 
and lactic acidosis led to its replacement by abacavir (ABC) for children and tenofovir (TDF) for 
adults.(3) Abacavir, although more expensive, has better short- and long-term side effect profile, 
and only requires monitoring soon after initiation.(3) It has been included, along with lamivudine 
(3TC) and either lopinavir/ritonavir (LPV/r) or efavirenz (EFV) in the first line paediatric regimen since 
2010.  
After the first-line NRTI backbone was changed, concerns were raised amongst clinicians about its 
efficacy. (3) (4) In an initial study of a single clinic in Johannesburg, rates of virological suppression at 
6 and 12 months were compared among 2036 children between 2004 and 2011. Children receiving 
ABC/3TC had statistically significantly lower rates of suppression, and longer time to achieve 
virological suppression. (4) A similar analysis was performed using pooled data from the IeDEA-
Southern Africa (International Epidemiologic Databases to Evaluate AIDS in Southern Africa) 
collaboration. 8 paediatric ART sites contributed data; 9543 children were analysed. 70% of young 
children on a d4T/LPV/r-containing regimen were virologically suppressed, compared to 54% of 
children receiving an ABC/LPV/r-containing regimen. Amongst older children receiving efavirenz, 
86% were virologically suppressed at 6 months while receiving d4T, compared to 78% of those 
receiving ABC. ABC was also associated with slower time to suppression and faster time to rebound 
after suppression, even after correcting for potential confounding factors.(5) As the data was 
obtained from routinely collected clinic data over several years, the authors could not determine 
whether the differences were due to intrinsic weakness of the ABC-containing regimen, or whether 
they were due to evolving social conditions and other programmatic changes that occurred at the 
same time. They recommended close monitoring and evaluation of paediatric ART programs.  
 
Until recently, there was very little data directly comparing d4T to ABC in paediatric populations (4). 
The PENTA 5 trial showed that ABC with 3TC combined with unboosted nelfinavir (NFV) performed 
better than zidovudine (ZDV) plus 3TC or ZDV plus ABC with upboosted NFV.(6) The CHAPAS-3 study, 
a parallel-group randomised controlled trial conducted in Zambia and Uganda, compared stavudine, 
zidovudine or abacavir in combination with lamivudine and nevirapine or efavirenz, and found no 
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major differences in any adverse event or toxicity endpoint during the nearly 2.5 year follow up in 
ART-naive and ART-experienced children. They also found children had a good clinical, 
immunological and virological response regardless of backbone NRTI. (7) Significantly, there was a 
very high retention in this intensively-monitored clinical trial: less than 5% were lost to follow up. In 
this context, unlike in the IDEA collaboration of routinely-collected clinic data, where adherence was 
not necessarily optimised, and retention was not ideal, abacavir was not inferior stavudine, 
suggesting that some of the effects observed in the Technau papers may have been due to patient 
factors, and not necessarily due to the drug itself.  
WHO guidelines which are followed by many Sub-Saharan countries have changed from using d4T to 
ABC ;(8,9) but in view of the Technau and Mulenga studies, and the limited paediatric ART 
formulations available, it is imperative that virological suppression of children receiving ABC-
containing regimens is monitored, as well as their adherence to medication and retention in care.  
 
Aims of the study  
This study aims to compare the percentage of children virologically suppressed at 6 months after 
commencing ART, comparing d4T to ABC-containing regimens. This will be stratified into under 1 
year, 1-3year and > 3years of age. The effect of concomitant TB treatment, stratified according to 
the same age bands, will also be assessed.  
 
Objectives  
To review viral suppression in an urban based regional hospital in the Western Cape, comparing d4T 
and ABC based regimens and the influence of TB, a common infection in the Western Cape 
population, on HIV viral suppression rates.  
 
Study design  
Retrospective analysis of routinely collected data (non-trial setting) of clinical notes as documented 
at a dedicated ARV clinic.  
 
Study setting and location  
The New Somerset Hospital (NSH) ARV Unit is a moderately sized urban HIV treatment centre in 
Cape Town, South Africa with an extensive drainage area that has been providing service to adults 
and children since 2005. National guidelines are followed, and children are routinely followed up at 
the clinic.  
 
Study Population  
Inclusion Criteria  
All HIV infected children < 16years old initiated on ART who were previously ART naïve (except for 
exposure to perinatal PMTCT prophylaxis) that were initiated on ART during study period: January 
2015 – January 2017.  
Exclusion Criteria  
Children attending the ARV clinic with insufficient data to identify patient or HIV status. 
 
Study Outcomes  
•Primary Outcomes:  
VL suppression (<50 RNA copies/ml) at 6months.  
Influence of TB treatment on viral load  
• Secondary Outcomes:  
Weight changes, as measured in weight-for-age z-score  
Retention in care review  




Study Procedures  
All clinical record folders of children < 16yrs of age that have been entered into the ARV clinic 
records will be reviewed and a data capturing questionnaire will be completed for each folder. 
Subjects will be de-identified once this information is captured.  
ART regimen, concomitant TB treatment, weight and height at initiation and follow up, as well as 
viral load measured at 6 months will be abstracted from the clinical notes. Adherence will be 
measured qualitatively, as assessed by clinician comments in the clinical notes and counselling 
records. Poor tolerability will be documented if specifically mentioned in the clinic notes by the 
attending clinician. Missed visits will be assessed by checking dates of attendance for clinic visits. 
Retention in care will be quantified, and percentages calculated of children remaining in active care 
at 6 months, discontinued ART, lost to follow up or transferred out.  
 
Statistical Methods  
Categorical variables will be described by simple percentages.  
Continuous variables will be described with medians and inter-quartile ranges  
Proportions of children virologically suppressed will be compared with p values and 95% confidence 
intervals  
 
Ethical Considerations  
The study will involve purely folder review and not physical contact with patients. The study will 
involve review of already collected data and there is no direct intervention or risk to patients or their 
families. All patient records will be kept confidential and each patient will be assigned a study 
number to maintain anonymity.  
 
Study Limitations  
Being a retrospective study based in a single site urban population both sample size and population 
bias may exist. There may be missing data, depending on the quality of the clinicians notes and the 
availability of the medical records. Retention of patients within the study population may be a 
limiting factor as well. The population, although diverse, may not be fully representative, as patients 
are limited to those who fell within the New Somerset Hospital drainage area and may have required 
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New Somerset Hospital Paediatric ARV Clinic Study 
Name : _______________________________              Folder No. :   
____________________________ 
 




Gender:           Male         Female 
Treatment (Rx)  initiated at NSH:  Yes   No 
(circle most applicable) 
 Regime started 
Date of diagnosis:     ____________________                   3TC  
 d4T  
 Date of Rx initiation:    __________________ ABC  
 AZT  
WHO staging at initiaton:   ________________ LPV/r  
 Efavirenz  
 NVP  
 Ritonavir  
 
TB Rx :   Pre- ARV initiation      At ARV initiation        <6/12 after ARV’s       > 6/12 post initiation or no 
TB dx 
(circle correct option) 
 
Date TB Rx started: _______________________           Date TB Rx stopped: ____________________ 
 
Viral Load:  At initiation: _______  At 6months: _________ 
       (within 5-8months post initiation) 
 
   Date: ____________  Date: _______________* 
 
  * if unavailable, why?     Missed follow up                           No Result                      Test not done          
Other 
         
Weight (kg):   At initiation: _______  At 6months: __________ 
    
   Weight for age: _____  Weight for age: ________ 
        (z-score)          (z-score) 
 
 Patient Adherence:  Commented to be poor    Good                              No comment 
(Clinical impression) 
 
Medication tolerated        Yes                                                 No 
Missed visits noted           Yes                                                No          
PMTCT exposure:  Yes   No    
 
PMTCT type:     Single dose NVP         Daily NVP            Prolonged daily NVP            AZT         Other 





 Office use only:   
 
  Study Applicable:       Yes              No 
  Further review required                  Yes      No 































Literature Review  
Objectives of literature review  
The objective of this literature review is to provide the reader with a background of HIV, particularly 
its temporal history with a focus on South African Paediatric HIV and its local and global 
advancement, temporal changes and rationale and the various evidence that lead to programmatic 
and regime guideline adjustments.  
Literature Search strategy  
The literature search was limited to English-language articles in MEDLINE  
(www.ncbi.nlm.nih.gov). Results were limited to humans. The following search string was used:  
(((("Stavudine"[Mesh]) OR stavudine) OR d4t)) AND (("abacavir"[Supplementary Concept]) OR 
abacavir)) AND (((((("Child"[Mesh]) OR "Child, Preschool"[Mesh]) OR "Infant"[Mesh]) OR 
"Adolescent"[Mesh])) OR (((((child) OR children) OR adolescents) OR pediatric) OR paediatric))  
All full text articles were reviewed and manual search from references of retrieved articles were 
added.  
Interpretation and summary of literature  
HIV continues to be a global public health concern, with the largest majority of affected people living 
in Sub-Saharan Africa. Despite global response from government and non-governmental 
organizations to reduce the HIV burden, in 2016, an estimated 36.7million people were living with 
HIV, 1.8 million of which were children less than the age of sixteen. (1)  
While great strides have been taken to provide improved access and availability for adults, Sub-
Saharan Africa is unique in that it is occupied by 12% of the global HIV population, but 
disproportionally almost 90% of children younger than 15yrs. (2). Limited access to paediatric 
antiretroviral drugs and availability of drugs in an appropriate formulation, amongst other 
challenges, has caused management of Paediatric HIV to lag far behind adult advancement.  
In May 2001, the first ARV project was started in the Khayelitsha community in Cape Town. The 
South African program unlike many other African countries, was primarily domestically funded and 
by April 2004, the national South African Antiretroviral therapy (ART) program was launched. (3) The 
expansion of the ART program also brought with it change in ART eligibility. In 2004, immunological 
and clinical criteria determined ART eligibility. Children with a World Health Organization (WHO) 
clinical classification stage 4 or CD4 percentage of < 10% were started on antiretroviral therapy. By 
2010, all children under the age of one year, regardless of CD4 or clinical stage were deemed 
eligible. By August 2012, the National Department of Health of South Africa, considered all HIV 
positive children under the age of 5, eligible for ART (4).  
The change in ART eligibility and advancement of research, also brought with it change in regime 
recommendations. There was agreement in management of HIV necessitating a 3 drug ART 
combination consisting of 2 Nucleoside Reverse Transcriptase Inhibitors (NRTI) and either a Protease 
Inhibitor (PI) or Non- Nucleoside Reverse Transcriptase Inhibitors (NNRTI).  
In 2004, children less than three years of age were initiated on stavudine, lamivudine and 
lopinavir/ritonavir, and children older than three years old, on stavudine, lamivudine and efavirenz 
as first line treatment. (4) The simplicity of d4T-containing regimens and low cost led to it becoming 
one of the most widely used ART drugs by 2010(5)  but by late 2003, d4T use had become associated 
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with metabolic toxicity and long-term complications of lipoatrophy, peripheral neuropathy and lactic 
acidosis, notably more pronounced in adults than in children. Initially WHO recommended that 
countries switch to a lower dose of d4T to minimize side effects. This did result in some 
improvement, but the overall frequency of side effects seemed to remain concerning from evidence 
in low-resource settings. South Africa, under these guidelines, in 2010, therefore recommended 
replacing stavudine with abacavir in all children experiencing side effects on stavudine. The 
recommended first line for all new patients initiating therapy also changed to either abacavir, 
lamivudine and lopinavir/ritonavir for children under 3yrs old and abacavir, lamivudine and efavirenz 
for older children. From 2013, most children, virologically suppressed, who were previously initiated 
in stavudine, were switched to abacavir. (4)  
After the first-line NRTI backbone was changed, however, from stavudine to abacavir, concerns were 
raised amongst clinicians about its efficacy. (6) (7) In an initial study of a single clinic in Johannesburg, 
rates of virological suppression at 6 and 12 months were compared among 2036 children between 
2004 and 2011. Children receiving ABC/3TC had statistically significantly lower rates of suppression, 
and longer time to achieve virological suppression. (7) Poorer virological outcomes were observed in 
children on abacavir-based regimes despite more favourable pre-treatment characteristics like 
weight for age, height for age and CD4 percentages. The improved pre-treatment characteristics 
were attributed to the expanding ART programme and more inclusive eligibility criteria. These 
virological differences were observed in both the lopinavir/ritonavir and efavirenz groups.  
A similar analysis was performed using pooled data from the IeDEA-Southern Africa (International 
Epidemiologic Databases to Evaluate AIDS in Southern Africa) collaboration. Eight South African 
paediatric ART sites contributed data which included 4 Cape Town based institutes and 2 
Johannesburg based sites, both within large metropolitan areas. 9543 children were included in the 
study and it was noted that 70% of young children on a d4T/LPV/r-containing regimen were 
virologically suppressed, compared to 54% of children receiving an ABC/LPV/r-containing regimen. 
Amongst older children receiving efavirenz. 86% were virologically suppressed at 6 months while 
receiving d4T, compared to 78% of those receiving ABC.  
ABC was also associated with slower time to suppression and faster time to rebound after 
suppression, even after correcting for potential confounding factors.(8) As the data was obtained 
from routinely collected clinic data over several years, the authors could not determine whether the 
differences were due to intrinsic weakness of the ABC-containing regimen, or whether they were 
due to evolving social conditions and other programmatic changes that occurred at the same time. 
They recommended close monitoring and evaluation of paediatric ART programs. (7) .  
 
Stavudine (d4T) was and is still thought to be a highly efficacious drug and has been shown to be less 
likely to develop drug related mutations when compared to zidovudine (AZT) containing regimes 
even in absence of strict virological monitoring. (9), It is also available in triple and dual combination 
scored dissolvable fixed dose combination (FDC) tablets, making paediatric dosing and possibly even 
adherence more achievable. (10). Stavudine containing regimens in 2011, were noted to be the least 
costly when compared to AZT-based and particularly ABC-based regimes. (11). Stavudine was also 
noted to be safer with regard to haematological disorders than AZT, which is of particular relevance 




The d4T FDC was amongst the first to be developed for children and was thus quite widely rolled out 
in Africa in large numbers. However, despite lipodystrophy being described in adults, it appears to 
be quite rare and poorly described in children, particularly those younger than 5years. Recent 
studies in children have also reported reversal of features of lipodystrophy on stopping d4T 
containing regimens in those that did develop lipodystrophy. (14-15) and understanding as to when to 
substitute children on d4T remains unclear, particularly in Africa. 
 
Abacavir (ABC), a NRTI, was recommended by the World Health Organisation (WHO), as both a first-
line and second-line ART regime agent, as well as amongst other European and American 
guidelines.(16-18)It is often prescribed with 3TC and the Arrow trial reported that the pharmacokinetics 
of ABC and 3TC were compatible with a once daily dose and showed good tolerance in those greater 
than 3 months.  
 
Randomised control trial evidence to support the superiority of ABC stemmed from the Pediatric 
European Network for Treatment of AIDS (PENTA 5) trial published in 2007, which showed that ABC 
with 3TC combined with upboosted nelfinavir (NFV) performed better than zidovudine (ZDV) plus 
3TC or ZDV plus ABC with upboosted NFV.(17) The study was conducted amongst 126 randomised 
children in a relatively high resourced setting. It consisted of mostly older children with a median age 
of 5.7years and much lower viral load (5.1 log10 copies/ml) and CD4 of 20% with only 11 (9%) of 
children having an AIDS defining illness unlike our South African cohorts (7). Contextualising this study 
to the South African context is difficult as the trial included asymptomatic children on dual therapy 
as well as used nelfinavir instead of lopinavir/ritonavir or efavirenz. There were concerns that the 
recommendation was done with low certainty of evidence.  
 
Hypersensitivity reactions associated with ABC remains a concern with children. Amongst adults a 
systematic review demonstrated a strong relation between the abacavir related hypersensitivity 
reaction and the HLA B5701 allele genotype (18) as well as increase risk of myocardial infarction. (19) 
While the PENTA5 trial showed superior virological effectiveness of 3TC and ABC over AZT and 3TC 
or AZT and ABC, the CHAPAS 3 trial done in Africa did not demonstrate this.  
 
The CHAPAS-3 (Children with HIV 1 in Africa, Pharmacokinetics and Adherence/Acceptability of 
Simple Antiretroviral Regimens) trial in 2015, was the first randomised controlled trial in African 
children to compare the three backbone NRTI’s for antiretroviral treatment (ART) regimens (20). It 
was an open-label, parallel-group randomised phase II/III trial conducted in Zambia and Uganda to 
evaluate new solid, dispersible scored antiretroviral fixed-dose combination and single drugs in 
African children. A total of 478 children (aged 1 month to 13 years) were randomised to study arms 
which received fixed-dose combination tablets of one of the three NRTIs (abacavir, stavudine, or 
zidovudine) plus lamivudine in combination with nevirapine or efavirenz. All combinations were 
dosed according to WHO weight bands. The trial included 365 ART-naive children and 113 
virologically suppressed ART-experienced children on a stavudine-containing first-line regimen for 2 
years or more. The trial compared the pharmacokinetics, toxicity, acceptability, adherence, efficacy 
and cost-effectiveness of these first-line antiretroviral regimens. (20)  
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Clinical outcomes for all three NRTIs presented low (4%) mortality, high (≥80%) viral load 
suppression rates in ART-naive children, high (>96%) maintenance of viral suppression at 48 weeks in 
ART-experienced children, and no evidence of differential CD4% recovery across randomised groups. 
It also found no major differences in any adverse event or toxicity endpoint during the nearly 2.5 
year follow up in ART-naive and ART-experienced children. (20)  
All three NRTI backbones with efavirenz or nevirapine were shown to have low toxicity and to 
produce high viral load suppression rates independent of the NRTI used. Abacavir has very low 
toxicity in African children, a superior resistance profile for second-line NRTI sequencing and is the 
only once-daily licensed NRTI fixed-dose combination (with lamivudine) for children, supporting its 
preferred use in first-line ART. (20) Significantly, there was a very high retention in this intensively-
monitored clinical trial: less than 5% were lost to follow up. In this context, unlike in the IDEA 
collaboration (8) of routinely-collected clinic data, where adherence was not necessarily optimised, 
and retention was not ideal, abacavir was not inferior stavudine, suggesting that some of the effects 
observed in the Technau papers (7)(8) may have been due to patient factors, and not necessarily due 
to the drug itself.  
Recently, the Cassim study (21), looked at the efficacy of abacavir versus stavudine in South African 
children and was based at the Paediatric Wellness Programme (PWP) at the Perinatal HIV Research 
Unit in Soweto, a prospective cohort of HIV1 infected children, the majority of whom are perinatally 
infected. The retrospective cohort study identified 57 eligible ABC cases and 114 matched d4T cases. 
Only children who were ART naïve at time of enrolment and who had initiated ART < 3years age 
were included. The groups shared similar temporal distribution to other South African cohorts with 
most d4T participants visits ranged from 2005 – 2011 and ABC between 2010 – 2013 with a median 
age of 3.11 (IQR: 1.98 – 6.05) months. Pre-ART, it was noted more children in the ABC group had a 
viral load < 100000 copies/ml (17.8% vs 2.8%) however no difference in virological, immunological 
and clinical outcomes were noted between children receiving ABC or d4T based antiretroviral 
therapy in Soweto. No difference in anthropomorphic measures of HAZ, WAZ and WLZ at 6months 
and 12months and no difference in the proportion of children with adherence levels > 90% for ABC 
and d4T based groups were appreciated either. (21) Whilst PWP is a programmatic cohort, it is run 
from within a well-established research unit by healthcare workers trained in the implementation of 
clinical trials and the stringent management implemented here, and this may not be as well 
appreciated in resource-low settings.  
 
Concerns are also raised on reviewing recent data on rapid clearance of ABC and whether current 
dosing recommendations , particularly in children and adolescents are high enough to avoid 
subtherapeutic levels. (22) Studies have inferred that the combination of inadequate dose changes 
during growth and development, incomplete viral suppression, adherence issues and lack of access 
to adequate paediatric ART formulations may all contribute to treatment failure and ART resistance. 
Sequencing of ART regimens after first line regimen failure becomes difficult in low- or middle-
income countries (LMIC) with limited ART available options, which often rely on WHO 
recommendations and cost considerations. WHO recommendations suggest that 3TC in combination 
with either AZT or d4T, be replaced by ABC and didanosine (ddl), however to note that very little 
data from LMIC was available at the time the guidelines were published to validate the 
recommendations.(23). A study in Kampala, of children failing NRTI-NNRTI regimes showed that only 2 
of 19 children would have been fully susceptible to ABC, ddl, and ritonavir-boosted lopinavir as a 
suggested WHO empiric second-line treatment (24). With very little access to resistance testing in 
many LMIC, this becomes problematic. Failure after using ABC may result in the acquisition of K65R 
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mutation with possibly prevents subsequent use of tenofovir later, making long term management 
more difficult.  
 
Conclusion  
Up until very recently, very little good evidence was available with regard to optimising paediatric 
HIV care. Guidelines still rely heavily on adult studies which is not always be related to paediatric 
needs or physiology. Limited paediatric drug availability and appropriate formulations make 
management and interpretation of programs difficult. The New Somerset Hospital ARV unit, a 
unique multicultural urban unit have been following WHO and South African National Health 
guidelines since its inception but very little is known about its efficacy as a unit or if the findings of 
this unit mirror the concerns of the Technau studies with similar challenges or the more research-
like units noted no particular differences in regimes. This study aims to explore the New Somerset 
Unit Paediatric unit to best optimise care for its patients. This study aims to compare the percentage 
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Paediatric antiretroviral therapy (ART) in Sub-Saharan Africa and other low-resource settings has 
demonstrated good early outcomes and studies in high-income countries have demonstrated that 
ART use among children effectively reduces morbidity, hospital admissions and increases long-term 
survival. (1) Lack of affordable and appropriate paediatric formulations have limited ART options in 
South Africa. (2)  
Initially, the South African ART programme used stavudine (d4T) as a first-line nucleoside reverse 
transcriptase inhibitor (NRTI). Stavudine was palatable and stable at room temperature, had few 
initial complications, and was relatively inexpensive. However late complications like lipodystrophy 
and lactic acidosis, more pronounced in adults than children, led to its replacement by abacavir 
(ABC) for children and tenofovir (TDF) for adults.(3) Abacavir, although more expensive, is thought to 
have a better short- and long-term side effect profile, and only requires monitoring soon after 
initiation.(3) It has been included, along with lamivudine (3TC) and either lopinavir/ritonavir (LPV/r) or 
efavirenz (EFV) in the first line paediatric regimen since 2010.  
After the first-line NRTI backbone was changed, concerns were raised amongst clinicians about its 
efficacy. (4,5) In an initial study of a single clinic in Johannesburg, rates of virological suppression at 6 
and 12 months were compared among 2036 children between 2004 and 2011. Children receiving 
abacavir/3TC had statistically significantly lower rates of suppression, and longer time to achieve 
virological suppression. (4) A similar analysis was performed using pooled data from the IeDEA-
Southern Africa (International Epidemiologic Databases to Evaluate AIDS in Southern Africa) 
collaboration (6). Eight paediatric ART sites contributed data; 9543 children were analysed. 70% of 
young children receiving stavudine/LPV/r-containing regimen were virologically suppressed, 
compared to 54% of children receiving an abacavir/LPV/r-containing regimen. Amongst older 
children receiving efavirenz, 86% were virologically suppressed at 6 months while receiving 
stavudine, compared to 78% of those receiving abacavir. Abacavir was also associated with slower 
time to suppression and faster time to rebound after suppression, even after correcting for potential 
confounding factors.(6) As the data was obtained from routinely collected clinic data over several 
years, the authors could not determine whether the differences were due to the intrinsic weakness 
of the abacavir-containing regimen, or whether they were due to evolving social conditions and 
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other programmatic changes that occurred at the same time. They recommended close monitoring 
and evaluation of paediatric ART programs.  
WHO guidelines which are followed by many Sub-Saharan countries have changed from using 
stavudine to abacavir;(7,8) but in view of the concerns of virological suppression using abacavir, 
ongoing surveillance of abacavir efficacy is needed. This study aims to compare the percentage of 




The study was a retrospective patient record review conducted at New Somerset Hospital, an urban 
secondary level government hospital within the Cape Town central business district, providing care 
to large mixed population drainage area. The antiretroviral (ARV) Referral Unit was initiated in 2005 
and serves both adults and children.  
 
Patient records of all HIV infected children less than 16 years of age at the time of initiation of 
treatment, who were initiated on treatment from January 2005 to January 2017, were identified. 
Patients with inconclusive HIV status or ART regime were excluded. HIV status of all patients was 
confirmed using HIV polymerase chain reaction (PCR) in those less than 18 months and 2 separate 
enzyme-linked immunosorbent assay (ELISA) tests on those older than 18 months prior to entering 
the clinic database. Patients records were reviewed from the time they were initiated onto 
treatment up until the end of study date, or until they either died, were transferred out for care at 
another facility or were deemed lost to follow up.  
 
Demographic and clinical details, including laboratory results and ART initiation data, were routinely 
recorded by clinicians in paper records held in the ARV Referral Unit from 2005 to 2010; after 2010, 
data was also electronically captured to Tier.Net database. The paper-based summary folders in the 
ARV Referral Unit were reviewed; this was supplemented by comparison with the Tier.net database. 
All viral loads were processed in the same laboratory, the National Health Laboratory Service 
Virology laboratory at Groote Schuur Hospital, using NucliSens EasyQ HIV-1, (2008 - Sept 2010), 
Abbott M2000 Realtime, (Sept 2010 - June 2015) and Roche COBAS Ampliprep/COBAS Taqman (June 
2015- present). Children were considered virologically suppressed if the viral load was undetectable, 
i.e. below the limit of detection of the assay that was being used at that time.  
 
Where enough information was available, an assessment was made of patient adherence and 
medication tolerability, as well as prevention of mother to child transmission (PMTCT) programme 
exposure and World Health Organisation (WHO) clinical staging. Tolerability was assessed by the 
attending clinician at the time of the patient’s clinic visit. Adherence was  
inferred by clinical suspicion and whether regular follow up was fulfilled as medications were only 
supplied with each visit. Children were considered “lost-to-follow-up” if there were no documented 
clinical visits within the first 6 months.  
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Study approval was obtained from the Western Cape Government Health Research Department 
(WC_2017RP43_111) and ethics approval from the University of Cape Town Faculty of Health 
Sciences Human Research Ethics Committee (HREC Ref 236/2017).  
 
Statistical Analysis  
Data was captured in Excel; analyses were performed in Stata (College Station, Texas, USA). 
Categorical variables were described using percentages, continuous variables using and medians and 
inter-quartile ranges. We compared risk of virological unsuppression at 6 months with or without 
tuberculosis (TB) treatment and on different ART regimens using crude and adjusted prevalence 
ratios from modified Poisson regression, with robust error variance estimation (9) . 
 
Results  
From 2005 – 2017, 672 children initiated ART at New Somerset Hospital; 529 (84%) were classified as 
WHO stage of 3 or 4 disease severity at time of initiation of ART, 51 (7.5%) as stage 1 or 2, and 92 
(13.5%) had no documented stage. More children (437, 65%), received a stavudine-containing 
regimen than an abacavir-containing regimen (181, 27%); the median ages were similar, table 1. 
More children receiving stavudine were transferred out (15% vs 0.5%), were lost to follow up (11% 
vs 1%) or died (3% vs 0.5%); and only 33% of children initiated on stavudine had a 6-month viral load 
result, compared to 50% of those initiated on abacavir. Tolerability and adherence were reported to 
be better with abacavir compared to stavudine, but information was frequently not available.  
 
Regimens consisted of 2 nucleoside or nucleotide reverse transcriptase inhibitors (NRTI’s): 
lamivudine, and one of either stavudine, abacavir or zidovudine. In addition, children received either 
a protease inhibitor, lopinavir/ritonavir (LPV/r) or a non-nucleoside reverse transcriptase inhibitor 
(NNRTI), efavirenz (EFV). Children receiving lopinavir-ritonavir were younger than those receiving 
efavirenz, table 2. Of the 229 children with a 6-month viral load result, more children receiving 
stavudine were virologically suppressed compared to abacavir: 56% for stavudine/LPV/r compared 
to 39% for abacavir/LPV/r, and 73% for stavudine/EFV compared to 50% for abacavir/EFV, table 2 
and figure 1.  
 
In addition, children commenced on treatment for tuberculosis (TB) at the time of ART initiation or 
within the first 6months after ART initiation were less likely to be virologically suppressed at 
6months than children not treated for tuberculosis. Of 23 children commenced on early TB 
treatment, 14 (61%) were unsuppressed, compared to 95 of 213 children (45%) who did not receive 
TB treatment in the first 6months of ART, risk ratio 1.36 (95% CI 0.95 – 1.96, p=0.09), table 3.  
 
There was an increased risk of being virologically unsuppressed at 6 months while using an abacavir-
containing regimen compared to a stavudine-containing regimen. This was statistically significant for 
the children using lopinavir-ritonavir, but not for those using efavirenz. The unadjusted risk of being 
virologically unsuppressed at 6 months while using abacavir/LPV/r was 1.39 (95% confidence interval 
1.03 to 1.88, p=0.04) compared to stavudine/LPV/r. The relative risk of virological unsuppression of 
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abacavir compared to stavudine was greater among children using efavirenz (1.82, 95% CI 0.98 – 
3.39, p=0.06), and was unchanged by concomitant TB treatment status.  These estimates however 
lacked precision due to limited sample size of children using efavirenz.  There was a trend towards 
lower risk of virological unsuppression among older children, but this was not statistically significant, 
table 3.   Other thresholds of virological suppression (<40 copies per ml, less than 100 copies per ml) 
showed similar inferences, but precision was limited by small sample size (data not shown). Other 
analysis-based multivariable comparisons were not possible due to the small sample size in the sub-
groups that were analysed.  
 
Discussion  
Our study reviewed a 12 year period in an urban centre, we observed an increased risk , at 6months 
post ART initiation, of being virologically unsuppressed while taking abacavir compared to stavudine 
(unadjusted risk 1,39, 95% CI 1.03 – 1.88, p=0.03) . This was similar to the results of the multi-cohort 
study of the IeDA Southern Africa collaboration from June 2014, which showed 54% of children were 
virologically suppressed on abacavir/LPV/r, versus 70% of children who were suppressed on 
stavudine/ LPV/r; and 78% were suppressed on abacavir-efavirenz, versus 86% who were 
suppressed on stavudine-efavirenz. (6)  
 
A recently published retrospective case-cohort study conducted in Soweto from 2005 to 2013 
reported no significant difference in virological suppression comparing children under 3 years using 
abacavir and stavudine. (10) However, the analysis was limited by a very small sample size, as only 57 
children using abacavir were included. The observed differences in virological suppression at 6 
months (54% versus 67%, Chi-squared p value 0.12) would have been statistically significant if they 
had used a larger sample size and would be congruent both with our results and with the IeDEA SA 
collaboration. (6)  
 
WHO guidelines for ARV initiation in children have evolved over time, from only initiating children 
with advanced clinical or immunological disease in 2010, (11) to recommending treatment for all HIV-
infected children irrespective of age or WHO staging. (7) At the time of introduction of abacavir, 
African children on abacavir were found to possess better pre-initiation characteristics than their 
predecessors initiated on other regimes prior to this. This is most likely because it coincided with the 
change in initiation criteria guidelines. (5) Furthermore, evidence suggests better outcomes in 
children who are initiated earlier; (12) and one would have expected to find better outcomes in those 
children with less severe immune suppression who were commenced on abacavir compared to 
those children with more severe disease who were commenced on stavudine.  
 
There are a number of possible reasons for the unexpected lower rate of virological suppression of 
children using abacavir in this study. The CHAPAS-3 study, a parallel-group randomised controlled 
trial conducted in Zambia and Uganda, compared stavudine, zidovudine or abacavir in combination 
with lamivudine and nevirapine or efavirenz, and found children had good clinical, immunological 
and virological response regardless of backbone NRTI. (13) They also found no major differences in 
any adverse event or toxicity endpoint during the nearly 2.5 years follow up of 480 ART-naive and 
ART-experienced children from November 2010- December 2011. (13) Notably, there was a very high 
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retention in this intensively-monitored clinical trial: less than 5% were lost to follow up. In this 
context, unlike our study and in the IeDEA collaboration of routinely-collected clinic data, (6) where 
adherence was not necessarily optimised, and retention was not ideal, the CHAPAS-3 trial did not 
find abacavir to be poorer in its virological response when compared to stavudine (13). It is also 
important to note only 24 of the ART-naïve children were younger than 1year, in contrast to our 
study, where 392 (58%) were younger than 1year, with associated high viral loads. This suggests that 
the differences we observed may not be due to intrinsic virological properties of the medications, 
but rather reflect the changing context of the expanding paediatric ART program.  
 
The extensive PMTCT roll out in South Africa during the study period decreased the overall number 
of vertically transmitted HIV cases (14) . We observed fewer children initiating ART in the later years 
of our cohort, figure 2. In addition to decreased burden of new infections, this also shows the effect 
of expanding access to community ART over time, as more children initiated ART at community sites, 
which has been a hallmark of the paediatric ART rollout.(15) As more children with uncomplicated 
disease were initiated at community sites, over the course of the study children with complex or 
severe disease, co-morbidities or social problems would have remained at the hospital-based clinic. 
This may have contributed to poorer adherence and virological suppression in the later abacavir era 
compared to the earlier years.  
 
Furthermore, as the PMTCT program led to marked decreases in peripartum and breastfeeding-
acquired infections, the relative proportion of intrauterine infected children has increased. (12) The 
effect on virological suppression on children with in utero infection may be different to children who 
are infected later, as the long-term impacts of HIV infection occurring in a foetus at a stage with a 
very immature immune system are not fully understood.  
 
Our study also displayed poorer virological suppression among children using LPV/r-based regimes 
compared to efavirenz-based regimes, in both abacavir and stavudine groups. As efavirenz was used 
in older children, the lower virological suppression among children using LPV/r may due to higher 
baseline viral loads in younger children and infants, making suppression more difficult. Furthermore, 
administration of LPV/r is problematic, as each dose comprises a small volume of very unpalatable 
syrup. Children may be more prone to spit out or vomit a dose of LPV/r than efavirenz, which results 
in under-dosing, and may have contributed to lower suppression in this age group.  
 
Adherence in this retrospective study was difficult to measure, with variable subjective and objective 
comments recorded. Missed visits served as a more objective inference of adherence. Similar to a 
10-year cohort analysis from a rural hospital in South Africa, (16) abacavir was noted to have higher 
attrition rates than stavudine. Substantial attrition within the first 6 months was observed in this 
study. Viral load testing amongst both groups was also poor, with only 145 (33%) of children using 
stavudine and 91 (50%) of children using abacavir having a documented viral load at 6 months. 
Other South African paediatric studies have documented viral load testing of 60 – 80% in urban 
centres and 40-45% in rural facilities. (14,16-18) It was reported that implementation of VL testing was 
particularly poor at facilities with large catchment populations (district or regional hospitals) 
compared to primary healthcare facilities. (16,19) It is uncertain whether this is due to temporal 
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changes in health-seeking behaviour, higher transportation costs and waiting times to accessing an 
urban facility, or decreased time spent counselling patients during busy clinics by overworked staff. 
In our cohort, it was also not clear whether the attending clinician deliberately deferred viral load 
testing if poor adherence or tolerability was reported. The lack of uniform follow-up testing 
guidelines within the clinic may have also contributed to infrequent or inconsistent testing.  
 
Cape Town, has a high incidence of tuberculosis. In 2000, the incidence was 562 new cases per 100 
000 population, with children under 15 years of age forming between 15% and 20% of this TB 
burden. (20) In our study the presence of TB was found to be unusually low; we suspect this was 
systematically under-reported, but we could not confirm this.  
 
Most deaths occurred within the first 3 months on treatment; this may reflect the baseline clinical 
severity of participant at initiation, rather than specific ART regimen. The decline in early deaths 
(within 6 months of initiation of ART) with abacavir regimes in the latter part of this study may 
reflect increased and earlier access to ART.  
 
There were several limitations in this analysis. This data is not that of a clinical trial, but of a busy 
public-sector clinic with high staff turnover and large patient numbers. Due to resource constraints, 
there were many missing variables, limiting statistical analysis of some outcomes. The groups 
compared were not randomised, but were initiated over different temporal periods, and initiation 
criteria and social environments varied markedly, making direct comparisons of the participants at 
baseline as well as the regimens used difficult. The study was also conducted at a single centre and 
with limited follow-up, only 6 months, with suboptimal and infrequent rates of viral load testing. 
This unique setting makes it difficult to extrapolate our results to the other paediatric populations at 
other time periods. However, use of routine program data rather than dedicated clinical trial 
databases may have enhanced representativeness, as it is likely to be a better reflection of the “real 




The overall rate of virological suppression we observed for all regimens was lower than that 
reported in the IeDEA collaboration (6) and in a recent analysis from Soweto. (10) Although of small 
sample size and limited by substantial missing data, this study offered an opportunity to describe an 
urban ART facility and contextualize our outcomes to current local and international data.  
 
Our analysis again raises concerns about virological suppression in the abacavir era of paediatric 
ART, compared to the previous stavudine era, particularly in combination with LPV/r in the younger, 
more vulnerable children. Whether this is because of intrinsic properties of the different 
medications or is a marker of the evolving complexity of the South African ART rollout, may never be 
resolved. However, this is of concern as abacavir and LPV/r appear to be entrenched as first-line 
paediatric ART in a setting where attrition is high, many children are lost to follow up and virologic 
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surveillance is not always optimal. Clinicians need to optimize retention strategies, especially of 
young infants, to ensure that children are retained in care, have viral load testing timeously, so that 
those virologically unsuppressed can be detected and treated early and appropriately.  
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Tables and figures 
 





containing regimen  
(n=181) 
Neither abacavir 
nor stavudine in 
initial regimen 
(n=54 
Age in months at initiation, median 
(Interquartile Range) 
8.9 (4.1; 24.1) 11.0 (3.5; 29.9) 3.1 (0.8; 10.0) 
Male sex, (%) 219 (50%) 88 (49%) 19 (35%) 
TB diagnosis:  
  Never, (%) 
  Before ART, (%) 
  At ART, or within 6 months, (%) 

















   Transferred out, (%) 
   Died, (%) 
   Lost to follow up, (%) 
   Retained in care, but no 6-month 
viral load, (%) 






















Poor adherence to medication noted, 
(%) 
15/111 (13%) 2/163 (1%) 
 
0 
Poor tolerability of medication 
noted, (%) 
17 /108 (16%) 4 /162 (2%) 1/33 (3%) 









Age (months) at 
initiation 
Median (IQR) 
Number with 6-month 





Stavudine /  
Lopinavir-
ritonavir 
318 6.9 (3.6; 15.4) 102/318 (32%) 57/102 (56%) 
Abacavir /  
Lopinavir-
ritonavir 
125 7.0 (3.0; 16.8) 57/125 (46%) 22/57 (39%) 
Stavudine /  
Efavirenz 
109 39.4 (9.4; 82.7) 40/109 (37%) 29/40 (73%) 
Abacavir /  
Efavirenz 























Stavudine / efavirenz Abacavir / efavirenz
Suppressed VL Unsuppressed VL
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Table 3: Risk of virological unsuppression at 6 months, using different antiretroviral regimens and 
tuberculosis treatment, from modified Poisson regression  
Regimen and comparison Risk ratio (95% confidence interval) P value 
Age at ART initiation:  
   Under 1 year (comparator) 
   1 to 3 years 
   Over 3 years 
 
1 
0.97 (0.70 – 1.34) 





TB treatment1 vs no TB treatment2  1.36 (0.95 – 1.95) 0.09 
Using LPV/r3: 
    ABC4 vs d4t5, unadjusted 
    ABC vs d4T, adjusted for TB treatment 
 
1.39 (1.03 – 1.88) 





    ABC vs d4t, unadjusted 
    ABC vs d4T, adjusted for TB treatment 
 
1.82 (0.98 – 3.39) 





1. Tuberculosis, diagnosed at ART initiation or within 6 months after ART initiation 
2. Never treated for TB, or not within 6 months of ART initiation 

















2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Number of new paediatric ART initiations 
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